GSK, Human Genome Escalate $2.6B Buyout Battle
GlaxoSmithKline PLC on Friday tried for the second time this month to entice Human Genome Sciences to agree to a $2.6 billion buyout, but the biopharmaceutical company rejected the unsolicited offer...To view the full article, register now.
Already a subscriber? Click here to view full article